No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers

被引：0
|
作者：
Marshall, William L. [1 ]
Marenco, Ted [2 ]
Feng, Hwa-Ping [1 ]
Barbour, April M. [1 ]
Gilmartin, Jocelyn [1 ]
Liu, Fang [1 ]
Panebianco, Deborah L. [1 ]
Mirzac, Angela [2 ]
Di Spirito, Mike [2 ]
Stypinski, Daria [2 ]
Machnes, Ziv [2 ]
Gartner, Michael [2 ]
Iwamoto, Marian [1 ]
Butterton, Joan R. [1 ]
Yeh, Wendy W. [1 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] Celerion, Lincoln, NE USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
730
引用
收藏
页码：573A / 573A
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics, Safety, and Tolerability of EDP-239, a Novel Hepatitis C NS5A inhibitor, in Healthy Volunteers
    Jiang, Lijuan
    Jiang, Xuemin
    Dole, Kiran
    Caliri, Kimberley
    Tack, Kenneth
    Colvin, Richard
    Or, Yat Sun
    HEPATOLOGY, 2015, 62 : 1307A - 1307A
  • [22] Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir
    Wyles, David
    Mangia, Alessandra
    Cheng, Wendy
    Shafran, Stephen
    Schwabe, Christian
    Ouyang, Wen
    Hedskog, Charlotte
    McNally, John
    Brainard, Diana M.
    Doehle, Brian P.
    Svarovskaia, Evguenia
    Miller, Michael D.
    Mo, Hongmei
    Dvory-Sobol, Hadas
    ANTIVIRAL THERAPY, 2018, 23 (03) : 229 - 238
  • [23] Lack of Clinically Relevant Pharmacokinetic Drug-Drug Interaction between Norgestimate/Ethinyl Estradiol and Pangenotypic HCV NS5A Inhibitor GS-5816 in HCV-Uninfected Female Subjects
    Mogalian, Erik
    Brainard, Diana M.
    McNally, John
    Shen, Gong
    Cuvin, Jennifer
    Mathias, Anita
    HEPATOLOGY, 2014, 60 : 1173A - 1173A
  • [24] Prevalence of natural polymorphisms at the HCV NS5A protein domain 1 associated with resistance to BMS-052, a NS5A inhibitor
    Plaza, Z.
    Soriano, V.
    Bar-Magen, T.
    Vispo, E.
    Gonzalez, M. M.
    Poveda, E.
    ANTIVIRAL THERAPY, 2011, 16 : A89 - A89
  • [25] Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers
    Jonsson, Martin
    Mundin, Gill
    Sumner, Michael
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 122 : 125 - 133
  • [26] Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy
    Hulskotte, Ellen G. J.
    Bruce, R. Douglas
    Feng, Hwa-Ping
    Webster, Lynn R.
    Xuan, Feng
    Lin, Wen H.
    O'Mara, Edward
    Wagner, John A.
    Butterton, Joan R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (03) : 303 - 311
  • [27] Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy
    Hulskotte, Ellen G.
    Feng, Hwa Ping
    Bruce, Robert D.
    Webster, Lynn R.
    Xuan, Fengjuan
    Lin, Wen Hong
    O'Mara, Edward
    Wagner, John A.
    Butterton, Joan R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 169 - 170
  • [28] Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy
    Ellen G. J. Hulskotte
    R. Douglas Bruce
    Hwa-Ping Feng
    Lynn R. Webster
    Feng Xuan
    Wen H. Lin
    Edward O’Mara
    John A. Wagner
    Joan R. Butterton
    European Journal of Clinical Pharmacology, 2015, 71 : 303 - 311
  • [29] DACLATASVIR DIHYDROCHLORIDE Treatment of Hepatitis C Virus HCV NS5A Inhibitor
    Reviriego, C.
    DRUGS OF THE FUTURE, 2011, 36 (10) : 735 - 739
  • [30] Pharmacokinetic Interaction Between Zolpidem and Carbamazepine in Healthy Volunteers
    Vlase, Laurian
    Popa, Adina
    Neag, Maria
    Muntean, Dana
    Baldea, Ioan
    Leucuta, Sorin E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (08): : 1233 - 1236
12345